Breaking News, Collaborations & Alliances

AstraZeneca, Alteogen Enter Agreement for Subcutaneous Formulations of Oncology Assets

To leverage Alteogen's ALT-B4 Hybrozyme platform technology for large volume subcutaneous administration of drugs.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Image: AstraZeneca

AstraZeneca and Alteogen Inc. have entered into an exclusive license agreement for ALT-B4, a novel hyaluronidase utilizing Hybrozyme platform technology. AstraZeneca will acquire worldwide rights to use ALT-B4 to develop and commercialize subcutaneous formulations of several oncology assets. Alteogen will be responsible for clinical and commercial supply of ALT-B4 to AstraZeneca. AstraZeneca will make an upfront payment to Alteogen and additional payments upon achievement of specific developm...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters